Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

On Thursday, JPMorgan adjusted its stance on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), downgrading the stock from Overweight to Neutral, despite increasing the price target from $52.00 to ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

SAN DIEGO, CA – In a recent transaction, Michael J. LaBarre, the Senior Vice President and Chief Technical Officer of Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ:HALO), sold shares of the ...

On Thursday, JPMorgan (NYSE:JPM) adjusted its stance on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), downgrading the stock from Overweight to Neutral, despite increasing the price target from ...

SAN DIEGO, CA – In a recent transaction, Michael J. LaBarre, the Senior Vice President and Chief Technical Officer of Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ:HALO), sold shares of the ...

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. (“Halozyme”) (NASDAQ: HALO) on behalf of the company’s shareholders. The ...